OncoSil Medical (ASX:OSL) FCF Margin %: -889.40% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:OSL OncoSil Medical Ltd ASX:OSL
48 GF Score
Price A$1.38
GF Value A$2.90
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is OncoSil Medical FCF Margin %?

OncoSil Medical ASX:OSL -1.79% 48 FCF Margin % is -889.40% as of Dec. 2025. GuruFocus rates ASX:OSL with a GF Score™ of 48/100 and a GF Value™ of A$2.90 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 816 Medical Devices & Instruments companies, OncoSil Medical ranks worse than 94.24% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. OncoSil Medical's Free Cash Flow for the six months ended in Dec. 2025 was A$-6.96 Mil. OncoSil Medical's Revenue for the six months ended in Dec. 2025 was A$0.78 Mil. Therefore, OncoSil Medical's FCF Margin % for the quarter that ended in Dec. 2025 was -889.40%.

As of today, OncoSil Medical's current FCF Yield % is -29.87%.

The historical rank and industry rank for OncoSil Medical's FCF Margin % or its related term are showing as below:

ASX:OSL' s FCF Margin % Range Over the Past 10 Years
Min: -4360.34   Med: -3090.76   Max: -863.88
Current: -863.88

During the past 13 years, the highest FCF Margin % of OncoSil Medical was -863.88%. The lowest was -4360.34%. And the median was -3090.76%.

ASX:OSL's FCF Margin % is ranked worse than
94.24% of 816 companies
in the Medical Devices & Instruments industry
Industry Median: -0.55 vs ASX:OSL: -863.88

OncoSil Medical FCF Margin % Related Terms

OncoSil Medical FCF Margin % Historical Data

* Premium members only.

The historical data trend for OncoSil Medical's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSil Medical FCF Margin % Chart

OncoSil Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4,163.85 -4,360.34 -3,090.76 -2,190.33 -1,031.34

OncoSil Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,894.32 -1,589.74 -1,334.64 -835.81 -889.40

ASX:OSL vs ABT, SYK, MDT: FCF Margin % Comparison

For the Medical Devices subindustry, OncoSil Medical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoSil Medical FCF Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OncoSil Medical's FCF Margin % distribution charts can be found below:

* The bar in red indicates where OncoSil Medical's FCF Margin % falls into.


ASX:OSL
48GF Score
OncoSil Medical Ltd ASX:OSL
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoSil Medical FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

OncoSil Medical's FCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-12.077/1.171
=-1,031.34 %

OncoSil Medical's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-6.964/0.783
=-889.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -889.40% mean?
OncoSil Medical (ASX:OSL) has a FCF Margin % of -889.40% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on OncoSil Medical and its competitors. According to the industry distribution chart, OncoSil Medical ranks #769 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 94.2%.
Is OncoSil Medical's FCF Margin % too high?
OncoSil Medical's current FCF Margin % is -889.40%. Based on the distribution chart, OncoSil Medical ranks #769 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, OncoSil Medical has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OncoSil Medical's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, OncoSil Medical ranks #769 out of 816 companies for FCF Margin %. This places OncoSil Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on OncoSil Medical and its competitors. OncoSil Medical's current FCF Margin % is -889.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSil Medical stock overvalued right now?
Based on GuruFocus' analysis, OncoSil Medical (ASX:OSL) is currently considered Possible Value Trap. The stock's GF Value™ is A$2.90, compared to a current price of A$1.38 — trading 52.6% below its estimated fair value. The current FCF Margin % is -889.40%. OncoSil Medical's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For OncoSil Medical (ASX:OSL), the current FCF Margin % is -889.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OncoSil Medical (ASX:OSL) Overvalued in 2026?

Based on GuruFocus' analysis, OncoSil Medical stock appears to be undervalued. The current stock price of A$1.38 is trading 52.6% below its estimated GF Value™ of A$2.90. GuruFocus considers OncoSil Medical to be Possible Value Trap.

Key valuation signals for ASX:OSL:

  • FCF Margin %: -889.40%
  • GF Value™: A$2.90 vs. price of A$1.38 (52.6% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the ASX:OSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OncoSil Medical Business Description

Address 7 Eden Park Drive, Level 5, Macquarie Park, Sydney, NSW, AUS, 2113
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
48GF Score

Get the complete analysis for ASX:OSL

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.38
Price
A$2.90
GF Value